25 November 2019 - Verastem today announced the submission of a marketing authorisation application to the European Medicines Agency for Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase, seeking approval for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma and relapsed or refractory follicular lymphoma.

Verastem Oncology is a commercial biopharmaceutical company committed to the development and commercialisation of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer.

Read Verastem press release